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Abstract
Background: Primary renal aspergillosis is rare in diabetic patients. Diagnosis of localized primary
renal Aspergillus  infection in diabetic patients requires careful investigations due to its benign
presentation and lack of associated systemic clinical features. There is also paucity of information
on the role of conservative treatment of such localized infection with antifungal agents only. Here,
we describe a case of localized renal aspergillosis in a type 2 diabetic patient with a brief review of
literature.
Case presentation: We describe a case of unilateral renal aspergillosis following intracorporeal
pneumatic lithotripsy (ICPL) in a type 2 diabetic man. The patient presented with mild pain in the
left lumbar region and periodic expulsion of whitish soft masses per urethra, which yielded growth
of Aspergillus fumigatus. He was treated initially with amphotericin B; however, it was stopped after
2 weeks, as he could not tolerate the drug. Subsequently, he was successfully treated with oral
itraconazole.
Conclusion: Localized renal aspergillosis may be suspected in diabetic patients having history of
urinary tract instrumentation, mild lumbar pain, passage of suspicious masses in urine and persistent
pyuria. Examination of the suspicious substances expelled per urethra is essential for diagnosis as
routine multiple urine analysis may yield negative results. Conservative treatment with oral
itraconazole alone is effective in cases with incomplete obstruction.
Background
Renal aspergillosis is a rare entity. Patients with compro-
mised immune status, such as diabetics, those on corticos-
teroid therapy and HIV positive individuals are more
vulnerable to infection by Aspergillus species [1]. A few
cases of renal aspergillosis have been reported in diabetics
[2-6]. Here, we describe a case of localized renal aspergil-
losis following ICPL and ureteric stenting in a diabetic
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man. He was successfully treated with oral itraconazole
without surgical intervention.
Case presentation
A 45-year-old man with type 2 diabetes was hospitalized
with complaints of mild pain in the left lumbar region,
irregular low-grade fever and occasional dysuria for 3
months. He occasionally passed whitish soft masses along
with urine for last two months and his loin pain aggra-
vated prior to passage of such soft masses per urethra.
Three months prior to hospitalization, he underwent ure-
teroscopy and ICPL for removal of stone in left kidney. A
stent was then placed in left ureter following ICPL. How-
ever, the stent was removed after 2 weeks as he developed
fever and lower abdominal pain, which did not respond
to antibiotic treatment. On physical examination, his vital
signs were normal. There was no lymphadenopathy, orga-
nomegaly or renal angle tenderness. Repeated routine
urine analysis revealed persistent pus cells (40–50 cells/
hpf) and occasional erythrocytes. Urine cultures were neg-
ative for bacteria and fungi on three consecutive samples.
No acid-fast bacilli were detected by Z-N stain in three
consecutive morning urine samples. Ultrasound scan and
intravenous urogram (IVU) revealed a cystic lesion (4 ×
3.9 cm) at lower pole cortical region of the left kidney.
Chest X-ray and tuberculin test were negative. Blood cul-
ture was negative and count was within normal limits
(Hb14.6 g/dl, total leukocyte count 10.8 × 109/L, neu-
trophils 57%, lymphocytes 33%, monocytes 04% and
eosinophils 10%, erythrocyte sedimentation rate 25 mm
1st hour, total platelet count 288 × 109/L). His serum cre-
atinine, urea, electrolytes and liver function tests were all
within normal range. Initially, his fasting blood glucose
level was 10 mmol/L and he was on oral hypoglycaemic
agent. His diabetes was controlled with insulin and fast-
ing blood sugar was maintained between 5.5–6.5 mmol/
L throughout the treatment period. A course of antibiotic
(ciprofloxacin 500 mg twice daily for 7 days) was given
without resolution of the symptoms.
Subsequently, microscopic examination of the soft whit-
ish masses (Fig. 1), which was expelled along with urine
revealed a mesh of fungal hyphae and upon culture
yielded growth of Aspergillus fumigatus. The case was diag-
nosed as a localized aspergillosis of the urinary tract.
Monotherapy with amphotericin B was planned and
accordingly the treatment was initiated with intravenous
amphotericin B 1.25 mg/kg/day. However, amphotericin
B had to be stopped after 2 weeks of treatment due to rise
in creatinine level, vomiting and weakness. Oral itracona-
zole (200 mg twice daily) was started. After one month, he
became symptom free and he ceased to pass whitish soft
masses (fungal ball) per urethra.
Itraconazole 200 mg twice daily was continued for a total
of two months and thereafter, the dose was reduced to
100 mg twice daily and continued for another four
months. He was followed regularly for 18 months. Repeat
IVU and ultrasound scan revealed resolution of cystic
lesion. He was symptom free 17 months after initiation of
itraconazole, and 12 months after stoppage of itracona-
zole. His renal function, liver function, routine urine anal-
ysis and culture were all normal. No surgical intervention
was required.
Discussion
The rate of urinary tract infection following ICPL and ure-
teric stenting is between 1 to 2% and around 3.5% respec-
tively and is mainly due to gram-negative bacteria [7-9].
So far, there is no report of Aspergillus infection of urinary
tract following ICPL. Aspergillosis of urinary tract may
occur by three ways namely, by ascending infection from
the lower tract, from haematogenous dissemination or
due to Aspergillus cast in renal pelvis [10]. Renal aspergil-
losis due to haematogenous dissemination is the most
common while localized infection is rare [10,11]. In our
case, no history of urinary tract infection and passage of
fungal masses per urethra prior to ICPL and instrumenta-
tion suggest that the Aspergillus was introduced into the
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urinary tract during ureteroscopy and placement of stent
in the ureter. Probably, fungal spores contaminated the
instrument during the procedure or the sterilization of the
equipment was inadequate. The infection was a primary
and localized aspergillosis of the urinary tract as no other
known focus of fungal infection was present elsewhere in
the body. Probably, the initial focus of infection origi-
nated in renal cortical tissue, which later extended and
opened into the pelvis or vice versa. The cystic lesion
observed in lower pole cortical region of the left kidney
and passage of fungal balls in urine indicated that it could
be a renal pelvis type aspergillosis as described by Den-
ning [12]. Renal stone, local tissue damage due to ICPL
and underlying diabetes facilitated the localized infection.
Initial multiple routine urine analysis and culture failed to
detect fungal hyphae and isolate Aspergillus until the whit-
ish soft masses expelled per urethra were examined. In our
patient, infection resolved completely with oral itracona-
zole and did not relapse after 18 months though poor
response to itraconazole in renal aspergillosis in diabetic
patient was noted [13].
Recently, improved outcome in invasive aspergillosis has
been reported by sequential therapy with amphotericin B
and itraconazole [14]. In our case, we planned mono-
therapy with amphotericin B and itraconazole was only
given when the patient did not tolerate amphotericin B.
Moreover, the patient continued to pass fungal balls dur-
ing amphotericin B and in first month of itraconazole
therapy. Therefore, we believe that initial amphotericin B
for two weeks was unable to clear the infection. Patient
only became symptom free and culture negative one
month after itraconazole therapy. Therefore, we assume
that though our patient received amphotericin B and itra-
conazole sequentially, in fact, the response was due to
itraconazole. However, we cannot entirely rule out the
beneficial effects of prior amphotericin B therapy as it has
been shown that the use of amphotericin B and itracona-
zole in sequence has synergistic effects and improved out-
come [14]. Moreover, there is a lack of specific
standardized sequential regime of amphotericin B and
itraconazole for each type of invasive aspergillosis except
for neutropenic patients [15]. Most important problem
being the optimum duration of initial amphotericin B
treatment before itraconazole can be started. Therefore,
the two weeks amphotericin B therapy that our patient has
received may or may not be adequate to have an optimum
effect on subsequent outcome.
Analysis of a large series of patients revealed that Aspergil-
lus infection of the kidney constitutes about 30% (27/90)
of total renal fungal infection and majority (63%) results
from disseminated infection [10]. Renal Aspergillus infec-
tion usually results from disseminated fungal infection
having underlying immunocompromised states. Co-exist-
ing conditions include malignancy, use of chemothera-
peutic and immunosuppressive agents, transplantation,
liver diseases, AIDS and diabetes [1,10,11]. However, pri-
mary renal aspergillosis in diabetic patients is rare. So far,
11 cases of renal Aspergillus infection in diabetic patients
have been reported between 1962–2006 [1-6,13,16-19].
Majority (63%) was male and 72% (8/10) had unilateral
involvement. A. flavus and A. fumigatus were equally and
most frequently isolated species. Clinical features ranged
from benign presentation to obstruction of urinary tract
and systemic complications. No typical symptoms of uri-
nary tract infection may be present. Fungal ball or bezoar
was present in 63% cases. Multiple routine examinations
of urine and cultures may be negative unless careful atten-
tion is given to the fungal masses expelled along with
urine. Systemic antifungal drug (amphotericin B) with or
without local irrigation and surgical intervention have
been the mainstay of treatment. However, successful out-
come of renal aspergillosis with conservative treatment
alone has also been reported [4,20]. Treatment of diabetic
patients having compromised renal function is difficult
with amphotericin B. In such cases, use of oral itracona-
zole in adequate dose as reported earlier and shown in our
case is a good alternative [19,21]. Use of oral itraconazole
even reduces the duration of hospital stay and has better
compliance due to less adverse effects. Voriconazole and
echinocandins (caspofungin) are new antifungal agents
with broad activity against wide variety of fungus includ-
ing  Aspergillus  sp [22,23]. These agents have improved
outcome and less toxicity compared to amphotericin B in
invasive aspergillosis. However, these agents are expensive
and the daily cost of therapy for voriconazole is US$ 67
compared to US$ 18–37 for itraconazole [24].
Conclusion
Our case suggests that localized renal aspergillosis may be
suspected when diabetic patients having history of urinary
tract instrumentation present with passage of suspicious
masses in urine. Specific examination of the suspicious
substance passed per urethra is essential for diagnosis of
renal aspergillosis as routine multiple urine analysis may
yield negative results due to intermittent excretion of fun-
gus in urine.
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